Bullish
Norges Bank Takes Position in Gilead Sciences, Inc. $GILD
Norges Bank has acquired a significant new stake in Gilead Sciences, purchasing 21.3 million shares valued at approximately $2.62 billion, representin...
GILD
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (50)
Neutral (29)
Bearish (2)
Latest GILD News
Bullish
Neutral
Gilead Sciences, Inc. $GILD Shares Sold by National Pension Service
National Pension Service lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 11.3% in the fourth quarter, according to...
Bearish
Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field
Gilead Sciences has halted development of GS-0272, a BTLA agonist acquired through its 2022 MiroBio buyout, which was intended to treat arthritis. Thi...
Bullish
National Pension Service Reduces Position in Gilead Sciences, Inc. $GILD
National Pension Service decreased its holdings in Gilead Sciences by 11.3% in the fourth quarter, selling nearly 380,000 shares to end with approxima...
Neutral
Gilead Sciences, Inc. $GILD Shares Sold by Ilmarinen Mutual Pension Insurance Co
Ilmarinen Mutual Pension Insurance Co decreased its stake in Gilead Sciences by 8.3% in the fourth quarter, selling 18,000 shares. Despite this, analy...
Bullish
Intech Investment Management LLC Buys 48,622 Shares of Gilead Sciences, Inc. $GILD
Intech Investment Management LLC increased its stake in Gilead Sciences (NASDAQ:GILD) by 19.9% in the fourth quarter, purchasing an additional 48,622 ...
Bullish
Fideuram Asset Management Ireland dac Buys Shares of 99,871 Gilead Sciences, Inc. $GILD
Fideuram Asset Management Ireland dac recently acquired a new stake of 99,871 shares in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter,...
Neutral
Geode Capital Management LLC Sells 232,984 Shares of Gilead Sciences, Inc. $GILD
Geode Capital Management LLC reduced its stake in Gilead Sciences (NASDAQ:GILD) by 0.8% in Q4, selling 232,984 shares but still retaining over 29.7 mi...
Bullish
Gilead liver drug Livdelzi normalizes key PBC marker in 2‑year study
Gilead Sciences announced interim Phase 3 ASSURE study data showing that its liver drug Livdelzi (seladelpar) normalized a key liver marker (ALP) in a...
Bullish
Flputnam Investment Management Co. Raises Holdings in Gilead Sciences, Inc. $GILD
Flputnam Investment Management Co. significantly increased its stake in Gilead Sciences, Inc. during the fourth quarter, boosting its holdings by 66.5...
Bullish
Eukles Asset Management Cuts Position in Gilead Sciences, Inc. $GILD
Eukles Asset Management significantly reduced its stake in Gilead Sciences, Inc. by 90.7% in the fourth quarter, selling 12,172 shares and retaining 1...
Neutral
Allstate Corp Buys 47,838 Shares of Gilead Sciences, Inc. $GILD
Allstate Corp significantly increased its stake in Gilead Sciences, Inc. by 105.7% during the fourth quarter, purchasing an additional 47,838 shares. ...
Bullish
GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
Gilead Sciences (GILD) received FDA accelerated approval for Hepcludex, the first FDA-approved therapy for chronic hepatitis delta virus (HDV) in the ...
Bullish
Todd Asset Management LLC Increases Stake in Gilead Sciences, Inc. $GILD
Todd Asset Management LLC increased its stake in Gilead Sciences (GILD) by 1.6% in the fourth quarter, reflecting institutional confidence. Gilead Sci...
Bullish
Simplify Asset Management Inc. Lowers Stake in Gilead Sciences, Inc. $GILD
Simplify Asset Management Inc. reduced its holding in Gilead Sciences by 37.7% in Q4, liquidating 22,707 shares, but still possessing 37,479 shares wo...
Bullish
Life Cycle Investment Partners Ltd Takes $1.42 Million Position in Gilead Sciences, Inc. $GILD
Life Cycle Investment Partners Ltd initiated a new $1.42 million position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, purchasing...
Neutral
Genus Capital Management Inc. Has $16.69 Million Position in Gilead Sciences, Inc. $GILD
Genus Capital Management Inc. decreased its stake in Gilead Sciences, Inc. by 26.7% in the fourth quarter, reducing its holdings to 135,986 shares val...
Bullish
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
Gilead Sciences' Chief Medical Officer, Dietmar Berger, outlined the company's clinical and regulatory priorities, emphasizing Trodelvy's potential in...
Bullish
LSV Asset Management Has $508.91 Million Position in Gilead Sciences, Inc. $GILD
LSV Asset Management has significantly reduced its stake in Gilead Sciences, Inc. by 3.6% during the fourth quarter, now holding 4,146,280 shares valu...
Bullish
Global Retirement Partners LLC Grows Position in Gilead Sciences, Inc. $GILD
Global Retirement Partners LLC significantly increased its stake in Gilead Sciences, Inc. during the fourth quarter, acquiring an additional 14,414 sh...
Research GILD on:
Ad Space